PIP Share Price

Open 0.73 Change Price %
High 0.73 1 Day -0.05 -7.14
Low 0.63 1 Week 0.00 0.00
Close 0.65 1 Month 0.00 0.00
Volume 871040 1 Year -1.88 -74.31
52 Week High 3.50
52 Week Low 0.47
PIP Important Levels
Resistance 2 0.74
Resistance 1 0.70
Pivot 0.67
Support 1 0.60
Support 2 0.56
AMEX USA Most Active Stocks
PAL 0.05 -50.00%
PAL 0.05 -50.00%
PAL 0.05 -50.00%
RBY 0.03 -70.00%
PBTH 8.23 0.37%
BTI 71.55 2.21%
BTI 71.55 2.21%
INO 6.01 0.00%
NGD 3.09 1.98%
NGD 3.09 1.98%
More..
AMEX USA Top Gainers Stocks
GGR 0.02 100.00%
ATC 0.37 60.87%
ATC 0.37 60.87%
ATC 0.37 60.87%
ATC 0.37 60.87%
MBA 0.20 25.00%
MBA 0.20 25.00%
MBA 0.20 25.00%
IG 7.68 22.49%
IG 7.68 22.49%
More..
AMEX USA Top Losers Stocks
RBY 0.03 -70.00%
PAL 0.05 -50.00%
PAL 0.05 -50.00%
PAL 0.05 -50.00%
QBC 0.20 -33.33%
ATL 0.06 -25.00%
ATL 0.06 -25.00%
PTX 3.43 -23.61%
PTX 3.43 -23.61%
SNT 0.12 -20.00%
More..

PharmAthene, Inc (AMEX: PIP)

PIP Technical Analysis 5
As on 4th May 2017 PIP Share Price closed @ 0.65 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 2.28 & Strong Sell for SHORT-TERM with Stoploss of 0.81 we also expect STOCK to react on Following IMPORTANT LEVELS.
PIP Target for July
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
PIP Other Details
Segment EQ
Market Capital 50784284.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.pharmathene.com
PIP Address
PIP
One Park Place
Suite 450
Annapolis, MD 21401
United States
Phone: 410-269-2600
Fax: 410-269-2601
PIP Latest News
Altimmune to Provide Corporate Update at the BIO International Convention   GlobeNewswire (press release)   - 19th Jun 17
Altimmune Promotes Dr. Sybil Tasker to Chief Medical Officer   GlobeNewswire (press release)   - 16th May 17
Altimmune, Inc. (Nasdaq: ALT) to Ring The Nasdaq Stock Market Opening Bell   Nasdaq   - 10th May 17
PharmAthene and Altimmune Announce Combined Company Approved for Trading on ...   GlobeNewswire (press release)   - 27th Apr 17
Altimmune Receives $7.3 Million Contract Modification from BARDA to Fund ...   GlobeNewswire (press release)   - 28th Mar 17
PharmAthene and Altimmune Announce Merger to Create Immunotherapeutics Company ...   PR Newswire (press release)   - 19th Jan 17
UPDATE -- Altimmune Announces Acceptance of HepTcell Abstract for Presentation ...   GlobeNewswire (press release)   - 06th Dec 16
Altimmune Announces Poster Presentation of HepTcell Program at 2017 Keystone ...   GlobeNewswire (press release)   - 26th Oct 16
Altimmune nabs $120.2 million federal contract for nasal spray anthrax vaccine   Washington Business Journal   - 11th Aug 16
Altimmune Inc.   Wall Street Journal (subscription)   - 16th Feb 11
Interactive Technical Analysis Chart PharmAthene, Inc ( PIP AMEX USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on PharmAthene, Inc
PIP Business Profile
PharmAthene, Inc., a biodefense company, develops and commercializes medical countermeasures against biological and chemical threats in the United States. Its product candidates include SparVax, a recombinant protective antigen anthrax vaccine for post-exposure prophylaxis in conjunction with antibiotics and general use prophylaxis; Valortim, a human monoclonal antibody to protect against and treat human inhalational anthrax; and recombinant butyrylcholinesterase bioscavenger, a medical countermeasure for nerve agent poisoning by organophosphorous compounds comprising nerve gases and pesticides. The company serves the United States Department of Defense, Chemical Biological Medical Systems, Biomedical Advanced Research and Development Authority, the National Institute of Allergy and Infectious Diseases, and the National Institute of Health. It has collaboration with Bristol-Myers Squibb for developing Valortim. The company is headquartered in Annapolis, Maryland.